The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson’s disease.

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...